Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 101 UK neurodegenerative disease companies below.
Ion channel drug discovery platform for rare CNS disorders
Autifony Therapeutics is a clinical-stage UK biotech developing small molecule modulators of Kv3 voltage-gated potassium channels for rare genetic CNS disorders. Lead programmes…
Transcription factor-targeting drug discovery for neurodegeneration
Scripta Therapeutics is an Oxford-based biotech company developing disease-modifying therapeutics by mapping and modulating transcription factor networks. Its platform integrates…
National institute researching dementia and neurodegenerative disease across the UK
The UK Dementia Research Institute is the UK's leading national institute dedicated to transforming outcomes for people affected by dementia and neurodegenerative conditions. Its…
Antibody immunotherapy targeting toxic tau for neurodegenerative disease
TauC3 Biologics is a preclinical biopharmaceutical company developing an antibody-based immunotherapy that targets tauC3, a toxic, truncated form of the tau protein implicated in…
Finnish pharma company marketing and developing medicines
Orion Pharma (UK) Limited is the UK subsidiary of Orion Corporation, a Finnish pharmaceutical company. The UK entity manages commercial operations for Orion's prescription…